ESMO ADVANCED COURSE PROGRAMME
BIOMARKERS FOR PRECISION IMMUNO-ONCOLOGY
ACROSS TUMOURS
Zurich, Switzerland
17-18 November 2023

CO-CHAIRS
Samra Turajlic, United Kingdom
Benedikt Westphalen, Germany

SPEAKERS
Roberto Figueroa Salgado, Belgium
Marie-Dominique Galibert, France
Michael Hubank, United Kingdom
Daniel Hübschmann, Germany
Lena Illert, Germany
Kevin Litchfield, United Kingdom
Christophe Massard, France
Miriam Molina, United Kingdom
Chantal Pauli, Switzerland
Etienne Rouleau, France

LEARNING OBJECTIVES

- To understand the concept of biomarker driven treatment
- To gain insights into the technical and clinical aspects of biomarker testing
- To understand the clinical implications of molecularly guided therapy options
- To integrate this knowledge into clinical decision making

Friday, 17 November

09:00-09:10  Welcome and introduction
10’  Welcome and Learning Objectives Introduction
Samra Turajlic, UK and Benedikt Westphalen, DE

09:10-10:45  Session 1 – Molecular target / Family of targets – DNA damage and mutational signatures
Chairs: Christophe Massard, FR and Samra Turajlic, UK

15’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
Etienne Rouleau, FR
5’  Q&A

15’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Daniel Hübschmann, DE
5’  Q&A

20’  Testing for the target / biomarker (assays, technicalitiesand practicalities, challenges for interpretation)
Chantal Pauli, CH
10’  Q&A

15’  A clinicopathological case presented and discussed by a Molecular Tumour Board
Benedikt Westphalen, DE
10’  Q&A
10:45-11:15  **Coffee break**

11:15-12:50  **Session 2 – Molecular target / Family of targets – FGFR**

Chairs: Chantal Pauli, CH and Benedikt Westphalen, DE

- 15’ Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
  * Lena Illert, DE*
  
- 5’ Q&A

- 15’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
  * Christophe Massard, FR*
  
- 5’ Q&A

- 20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
  * Marie-Dominique Galibert, FR*
  
- 10’ Q&A

- 15’ A clinicopathological case presented and discussed by a Molecular Tumour Board
  * Lena Illert, DE*
  
- 10’ Q&A

12:50-13:50  **Lunch**

13:50-15:25  **Session 3 – Molecular target / Family of targets – RAS**

Chair: Marie-Dominique Galibert, FR and Samra Turajlic, UK

- 15’ Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
  * Miriam Molina, UK*
  
- 5’ Q&A

- 15’ Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
  * Benedikt Westphalen, DE*
  
- 5’ Q&A

- 20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
  * Michael Hubank, UK*
  
- 10’ Q&A

- 15’ A clinicopathological case presented and discussed by a Molecular Tumour Board
  * Miriam Molina, UK*
  
- 10’ Q&A

19:30  **Networking Dinner**
Saturday, 18 November 2023

09:00-12:00  Session 4 – Molecular target / Family of targets – Immune infiltration and immune checkpoints  
Chair: Miriam Molina, UK and Benedikt Westphalen, DE

25’  Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)  
Kevin Litchfield, UK

10’  Q&A

25’  Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity  
Samra Turajlic, UK

10’  Q&A

20’  Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)  
Roberto Figueroa Salgado, BE

10’  Q&A

10:40-11:10  Coffee break

15’  A clinicopathological case presented and discussed by a Molecular Tumour Board  
Lena Illert, DE

10’  Q&A

15’  Value/health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWO)  
Michael Hubank, UK

10’  Q&A

12:00-12:15  Synthesis and wrap-up  
Samra Turajlic, UK and Benedikt Westphalen, DE

12:15-13:15  Lunch